The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular diseaseThe Task Force on ACE-inhibitors of the European Society of Cardiology
Open accessAbstract
ESC Committee for Practice Guidelines (CPG), Silvia G. Priori (Chairperson) (Italy), Maria Angeles Alonso García (Spain), Jean-Jacques Blanc (France), Andrzej Budaj (Poland), Martin Cowie (UK), Veronica Dean (France), Jaap Deckers (The Netherlands), Enrique Fernandez Burgos (Spain), John Lekakis (Greece), Bertil Lindahl (Sweden), Gianfranco Mazzotta (Italy), Keith McGregor (France), João Morais (Portugal), Ali Oto (Turkey), Otto A. Smiseth (Norway) Document Reviewers, Maria Angeles Alonso García (CPG Review Coordinator) (Spain), Diego Ardissino (Italy), Cristina Avendano (Spain), Carina Blomström-Lundqvist (Sweden), Denis Clément (Belgium), Helmut Drexler (Germany), Roberto Ferrari (Italy), Keith A. Fox (UK), Desmond Julian (UK), Peter Kearney (Ireland), Werner Klein (Austria), Lars Köber (Denmark), Giuseppe Mancia (Italy), Markku Nieminen (Finland), Witold Ruzyllo (Poland), Maarten Simoons (The Netherlands) Kristian Thygesen (Denmark), Gianni Tognoni (Italy), Isabella Tritto (Italy), Lars Wallentin (Sweden) Guidelines and Expert Consensus documents aim to present all the relevant evidence on a particular issue in order to help physicians to weigh the benefits and risks of a particular diagnostic or therapeutic procedure. They should be helpful in everyday clinical decision-making. A great number of Guidelines and Expert Consensus Documents have been issued in recent years by the European Society of Cardiology (ESC) and by different organisations and other related societies. This profusion can put at stake the authority and validity of guidelines, which can only be guaranteed if they have been developed by an unquestionable decision-making process. This is one of the reasons why the ESC and others have issued recommendations for formulating and issuing Guidelines and Expert Consensus Documents. In spite of the fact that standards for issuing good quality Guidelines and Expert Consensus Documents are well defined, recent surveys of Guidelines and Expert Consensus Documents published in peer-reviewed journals between 1985 and 1998 have shown that methodological standards were not complied with in the vast majority of cases. It is therefore of great importance that guidelines and recommendations are presented in formats that are easily interpreted. Subsequently, their implementation programmes must also be well conducted. The ESC Committee for Practice Guidelines (CPG) supervises and coordinates the preparation of new Guidelines and Expert Consensus Documents produced by Task Forces, expert groups or consensus panels. The chosen experts in these writing panels are asked to provide disclosure statements of all relationships they may have which might be perceived as real or potential conflicts of interest. These disclosure forms are kept on file at the European Heart House, headquarters of the ESC. The Committee is also responsible for the endorsement of these Guidelines and Expert Consensus Documents or statements. The Task Force has classified and ranked the usefulness or efficacy of the recommended procedure and/or treatment and the Level of Evidence as indicated in the tables below: Class I. Evidence and/or general agreement that a given procedure/treatment is beneficial, useful and effective. Class II. Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the procedure/treatment. Class IIa. Weight of evidence/opinion is in favour of usefulness/efficacy. Class IIb. Usefulness/efficacy is less well established by evidence/opinion. Class III*. Evidence or general agreement that the treatment is not useful/effective and in some cases may be harmful. *Use of class III is discouraged by the ESC. Level of Evidence A. Data derived from multiple randomised clinical trials or meta-analyses. Level of Evidence B. Data derived from a single randomised clinical trials or non-randomised studies. Level of Evidence C. Consensus of opinion of the experts and/or small studies. The renin-angiotensin system plays a major role in cardiovascular disease and during the past decade extensive research investigated the possible clinical benefit of the use of angiotensin converting enzyme inhibitors (ACE-I) in different clinical conditions. Accordingly, these agents have been recommended for the treatment of heart failure, hypertension, and acute and chronic myocardial infarction. The aim of this document is to review the rationale and clinical evidence for the use of ACE-I in patients with cardiovascular disease. The Task Force members for the Angiotensin Converting Enzyme Inhibitors in Cardiovascular Disease were nominated by the Committee for Practice Guidelines (CPG) of the European Society of Cardiology (ESC). A specific literature search was carried out for original articles in peer review journals included in Medline. In addition, the ESC as well as the American Heart Association/American College of Cardiology guidelines with reference to the use of ACE-I were carefully reviewed. Most of the previ
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,094
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
(1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271003 · Cited by 3,725
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Self-citationPfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471
Self-citationDe Backer, G. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00347-6 · Cited by 2,251
(2000) · PubMed · Cited by 2,095
Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Julian, D. G., Moss, A. J., Murray, G. D., Poole-Wilson, P. A., Simoons, M. L., Ball, S., Bender, N., Cleland, J. G. F., Dl, C., Pj, C., et al. (1993) · The Lancet · Cited by 1,860
Guidelines for the diagnosis and treatment of chronic heart failure
Remme, W. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2783 · Cited by 1,592
Flather, M. D., Yusuf, S., Køber, L., Pfeffer, M., Hall, A., Murray, G., Torp-Pedersen, C., Ball, S., Pogue, J., Moyé, L., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02212-1 · Cited by 1,585
Management of acute myocardial infarction in patients presenting with ST-segment elevation
VandeWerf, F. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00618-8 · Cited by 1,448
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & de Faire, U. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,447
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 1,406
Francis, G. S., Benedict, C., Johnstone, D. E., Kirlin, P. C., Nicklas, J., Liang, C. S., Kubo, S. H., Rudin-Toretsky, E., & Yusuf, S. (1990) · Circulation · doi:10.1161/01.cir.82.5.1724 · Cited by 1,388
Wood, D., De Backer, G., Faergeman, O., Graham, I., Mancia, G., & Pyörälä, K. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)90209-x · Cited by 1,255
Packer, M., Poole-Wilson, P. A., Armstrong, P. W., Cleland, J. G. F., Horowitz, J. D., Massie, B. M., Rydén, L., Thygesen, K., & Uretsky, B. F. (1999) · Circulation · doi:10.1161/01.cir.100.23.2312 · Cited by 1,244
Dickstein, K., & Kjekshus, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,203
Estacio, R. O., Jeffers, B. W., Hiatt, W. R., Biggerstaff, S. L., Gifford, N., & Schrier, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803053381003 · Cited by 1,166
Swedberg, K., Eneroth, P., Kjekshus, J., & Wilhelmsen, L. (1990) · Circulation · doi:10.1161/01.cir.82.5.1730 · Cited by 1,153
Second Joint Task Force of European (1998) · European Heart Journal · doi:10.1053/euhj.1998.1243 · Cited by 1,131
Wing, L. M. H., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L. R., Johnston, C. I., McNeil, J. J., Macdonald, G. J., Marley, J. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021716 · Cited by 1,130
GRUPPOITALIANOPERLOSTUDIODELL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90232-1 · Cited by 1,118
Collins, R. T., Peto, R., Flather, M. D., Parish, S., Sleight, P., Conway, M. A., Pipilis, A., Baigent, C., Barnett, D., Boissel, J., et al. (1995) · Ghent University Academic Bibliography (Ghent University) · Cited by 1,115
McMurray, J. J. V., Östergren, J., Swedberg, K. B., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer (2003) · The Lancet · Cited by 1,043
Swedberg, K., Held, P., Kjekshus, J., Rasmussen, K., Rydén, L., & Wedel, H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271002 · Cited by 964
Angiotensin-Converting Enzyme Inhibitors
Brown, N. J., & Vaughan, D. E. (1998) · Circulation · doi:10.1161/01.cir.97.14.1411 · Cited by 958
Cardiovascular protection and blood pressure reduction: a meta-analysis
Staessen, J. A., Wang, J.-G., & Thijs, L. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06411-x · Cited by 944
Israili, Z. H., & Hall, W. D. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-3-234 · Cited by 910
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Task Force on Sudden Cardiac Death of the European Society of Cardiology
Priori, S. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2824 · Cited by 903
Ambrosioni, E., Borghi, C., & Magnani, B. (1995) · New England Journal of Medicine · doi:10.1056/nejm199501123320203 · Cited by 787
Lonn, E. M., Yusuf, S., Dzavik, V., Doris, C. I., Yi, Q., Smith, S., Moore-Cox, A., Bosch, J., Riley, W. A., & Teo, K. K. (2001) · Circulation · doi:10.1161/01.cir.103.7.919 · Cited by 712
Neoptolemos, J., Kemppainen, E., Mayer, J., Fitzpatrick, J., Raraty, M., Slavin, J., Beger, H.-G., Hietaranta, A., & Puolakkainen, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02327-8 · Cited by 623
Schmieder, R. E. (1996) · JAMA · doi:10.1001/jama.1996.03530430051039 · Cited by 604
Franzosi, M. G., Santoro, E., Zuanetti, G., Baigent, C., Collins, R., Flather, M. D., Kjekshus, J., Latini, R., Liu, L., Maggioni, A. P., et al. (1998) · Circulation · Cited by 544
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.
Lonn, E. M., Yusuf, S., Jha, P., Montague, T. J., Teo, K. K., Benedict, C. R., & Pitt, B. (1994) · Circulation · doi:10.1161/01.cir.90.4.2056 · Cited by 503
(1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00465-1 · Cited by 494
Shekelle, P. G., Rich, M. W., Morton, S. C., Atkinson, C. S. W., Tu, W., Maglione, M., Rhodes, S., Barrett, M., Fonarow, G. C., Greenberg, B., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00262-6 · Cited by 492
Jong, P., Yusuf, S., Rousseau, M. F., Ahn, S. A., & Bangdiwala, S. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13501-5 · Cited by 378
Converting-Enzyme Inhibitors in the Treatment of Hypertension
Oates, J. A., Wood, A. J. J., & Williams, G. H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812083192305 · Cited by 364
Hornig, B., Landmesser, U., Kohler, C., Ahlersmann, D., Spiekermann, S., Christoph, A., Tatge, H., & Drexler, H. (2001) · Circulation · doi:10.1161/01.cir.103.6.799 · Cited by 341
Hornig, B., Kohler, C., & Drexler, H. (1997) · Circulation · doi:10.1161/01.cir.95.5.1115 · Cited by 333
Brown, N. J., Ray, W. A., Snowden, M., & Griffin, M. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90161-7 · Cited by 313
Teo, K. K., Burton, J. R., Buller, C. E., Plante, S., Catellier, D., Tymchak, W., Dzavik, V., Taylor, D., Yokoyama, S., & Montague, T. J. (2000) · Circulation · doi:10.1161/01.cir.102.15.1748 · Cited by 275
Dzau, V. J., Bernstein, K., Celermajer, D., Cohen, J., Dahlöf, B., Deanfield, J., Diez, J., Drexler, H., Ferrari, R., van Gilst, W., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01878-1 · Cited by 259
Vermes, E., Ducharme, A., Bourassa, M. G., Lessard, M., White, M., & Tardif, J.-C. (2003) · Circulation · doi:10.1161/01.cir.0000054611.89228.92 · Cited by 248
Interaction Between Sympathetic and Renin-angiotensin System
Zimmerman, B. G., Sybertz, E. J., & Wong, P. C. (1984) · Journal of Hypertension · doi:10.1097/00004872-198412000-00002 · Cited by 244
Philbin, E. F., Rocco, T. A., Lindenmuth, N. W., Ulrich, K., & Jenkins, P. L. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00601-x · Cited by 240
Tea, K. K., Yusuf, S., Pfeffer, M., Kober, L., Hall, A., Pogue, J., Latini, R., & Collins, R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11138-x · Cited by 238
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study
Arnold, J. M. O., Yusuf, S., Young, J., Mathew, J., Johnstone, D., Avezum, A., Lonn, E., Pogue, J., & Bosch, J. (2003) · Circulation · doi:10.1161/01.cir.0000054165.93055.42 · Cited by 236
MacMahon, S., Sharpe, N., Gamble, G., Clague, A., Ni Mhurchu, C., Clark, T., Hart, H., Scott, J., & White, H. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00736-1 · Cited by 235
Devereux, R. B., Palmieri, V., Sharpe, N., De Quattro, V., Bella, J. N., de Simone, G., Walker, J. F., Hahn, R. T., & Dahlöf, B. (2001) · Circulation · doi:10.1161/hc3601.095927 · Cited by 209
Schiffrin, E. L., & Deng, L.-Y. (1995) · Hypertension · doi:10.1161/01.hyp.25.4.699 · Cited by 192
Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison
(1998) · European Heart Journal · doi:10.1053/euhj.1997.0839 · Cited by 184
Torp-Pedersen, C., & Køber, L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09374-x · Cited by 171
Update of the guidelines on sudden cardiac death of the European Society of Cardiology
Priori, S. (2003) · European Heart Journal · doi:10.1016/s0195-0668x(02)00809-6 · Cited by 170
Interactions among ACE, kinins and NO
Linz, W. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00091-7 · Cited by 165
Ahuja, T. S., Freeman Jr., D., Mahnken, J. D., Agraharkar, M., Siddiqui, M., & Memon, A. (2000) · American Journal of Nephrology · doi:10.1159/000013599 · Cited by 114
Taddei, S., Virdis, A., Ghiadoni, L., Mattei, P., & Salvetti, A. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816040-00006 · Cited by 107
Invited Review Recognition and management of angiotensin converting enzyme inhibitor fetopathy
Sedman, A. B., Kershaw, D. B., & Bunchman, T. E. (1995) · Pediatric Nephrology · doi:10.1007/bf02254221 · Cited by 98
The chymase-angiotensin system in humans.
Husain, A. (1993) · PubMed · Cited by 98
Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet
Cashin-Hemphill, L., Holmvang, G., Chan, R. C., Pitt, B., Dinsmore, R. E., & Lees, R. S. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00780-2 · Cited by 98
Narang, R., Swedberg, K. B., & Cleland, J. G. F. (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a014670 · Cited by 92
Lotshaw, D. P. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00384-7 · Cited by 90
The Brain Renin-Angiotensin System: Localization and General Significance
Bunnemann, B., Fuxé, K., & Ganten, D. (1992) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199219006-00010 · Cited by 88
Brent, R. L., & Beckman, D. A. (1991) · Teratology · doi:10.1002/tera.1420430602 · Cited by 83
Clinical Pharmacokinetics of Angiotensin Converting Enzyme (ACE) Inhibitors in Renal Failure
Hoyer, J. D., Schulte, K.-L., & Lenz, T. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324030-00005 · Cited by 75
Lee, A. F. C., MacFadyen, R. J., & Struthers, A. D. (1999) · European Journal of Heart Failure · doi:10.1016/s1388-9842(99)00046-x · Cited by 72
Wood, R. A. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04447.x · Cited by 69
McMurray, J. J. V., Solal, A. C., Dietz, R., Eichhorn, E. J., Leif, E., Hobbs, R. F., Maggioni, A. P., Ileana, P., Soler‐Soler, J., & Swedberg, K. B. (2001) · European Journal of Heart Failure · doi:10.1016/s1388-9842(01)00173-8 · Cited by 69
Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors
Wynckel, A., Ebikili, B., Melin, J., Randoux, C., Lavaud, S., & Chanard, J. (1998) · American Journal of Hypertension · doi:10.1016/s0895-7061(98)00117-4 · Cited by 67
Angiotensin converting enzyme inhibitor associated cough: A population-based case-control study
Visser, L. E., Stricker, B. H. C., Velden, J. V. D., Paes, A. H. P., & Bakker, A. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00231-e · Cited by 64
Importance of Neuroendocrine Activation in Chronic Heart Failure. Impact on Treatment Strategies
Swedberg, K. B. (2000) · European Journal of Heart Failure · doi:10.1016/s1388-9842(00)00102-1 · Cited by 42
Kyriakidis, M., Triposkiadis, F., Dernellis, J., Androulakis, A. E., Mellas, P., Kelepeshis, G. A., & Gialafos, J. E. (1998) · Circulation · doi:10.1161/01.cir.97.14.1342 · Cited by 42
GUNDERSEN, T., Swedberg, K. B., Amtorp, O., Remes, J., & NILSSON, B. (1994) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a060449 · Cited by 30
Should exercise blood pressure be measured in clinical practice?
Tsao, T. P., Wright, D. J., & Tan, L. B. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816010-00003 · Cited by 20
Giannattasio, C., Grassi, G. M., Seravalle, G., Morganti, A., Zanchetti, A., & Mancia, G. (1989) · American Heart Journal · doi:10.1016/0002-8703(89)90764-3 · Cited by 18
Charlon, V., Dollow, S., Fidel, J., et al. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04418.x · Cited by 15
Gottlieb, S., Leor, J., Shotan, A., Harpaz, D., Boyko, V., Rott, D., Mandelzweig, L., & Behar, S. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.07.002 · Cited by 13
Boon, W. C., McDougall, J. G., & Coghlan, J. P. (1998) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1998.tb02365.x · Cited by 9
Cited by
Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2006) · Circulation · doi:10.1161/circulationaha.106.635144 · Cited by 1,026
The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic Inhibition
Atlas, S. A. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.s8-b.9 · Cited by 722
Lucas, G. M., Ross, M. J., Stock, P. G., Shlipak, M. G., Wyatt, C. M., Gupta, S. K., Atta, M. G., Wools-Kaloustian, K. K., Pham, P. A., Bruggeman, L. A., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu617 · Cited by 310
Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study
Hackam, D. G., Thiruchelvam, D., & Redelmeier, D. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69250-7 · Cited by 298
Agunloye, O. M., Oboh, G., Ademiluyi, A. O., Ademosun, A. O., Akindahunsi, A. A., Oyagbemi, A. A., Omobowale, T. O., Ajibade, T. O., & Adedapo, A. A. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.044 · Cited by 285
Metadata
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08
- Volume
- 25
- Issue
- 16
- Pages
- 1454-1470
- ISSN
- 0195-668X (ISSN-L)
- OpenAlex
- W2284008279
- Cited by
- 331
- References
- 95
- FWCI
- 15.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.